ERBB2 and non-small cell lung carcinoma: This study performed 14 cancer‐related gene alternation analyses in a lager Chinese NSCLC cohort (n = 3440), and identified 90.17% (3102/3440) of patients with at least one alteration, including TP53 (54.74%), EGFR (53.55%), KRAS (13.40%), ERBB2 (9.51%), ALK (7.82%), PIK3CA (6.34%), ROS1 (5.78%), RET (4.01%), MET (3.92%), BRAF (3.14%), KIT (3.05%), FGFR1 (1.98%), PDGFRA (1.86%), and NRAS (0.55%).